>
>
Alzheimer’s Therapeutics Market – By Drug Class (Cholinesterase Inhibitors, NMDA, Combination Drugs, Glutamate, MAO), Route of Administration (Oral, Injectable, Transdermal), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) & Forecast, 2024 – 2032
Download Free PDF

Alzheimer’s Therapeutics Market
Get a free sample of this reportGet a free sample of this report Alzheimer’s Therapeutics Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2023
Companies covered: 15
Tables & Figures: 120
Countries covered: 23
Pages: 100
Download Free PDF
Alzheimer’s Therapeutics Market Size
Alzheimer’s Therapeutics Market size was valued at USD 5.8 billion in 2023 and is expected to exhibit growth at a CAGR of 9.8% from 2024 to 2032. High market growth can be attributed to the ongoing advancements in diagnostic technologies, increasing prevalence of Alzheimer’s disease, expanding geriatric population, technological advancements in novel drug delivery system, and growing healthcare expenditure, among other contributing factors.
Moreover, the most significant driver is the rising prevalence of Alzheimer's disease globally. As the global population ages, the number of people diagnosed with Alzheimer’s disease continues to increase. For instance, according to Alzheimer's Association research published in 2023, an estimated 6.7 million Americans aged 65 and older had Alzheimer's disease, with the figure expected to rise to 13.8 million by 2060. Thus, the risk of Alzheimer’s increases with age, making it more common in the elderly population.
Furthermore, recent advancements in diagnostic technologies have made it easier to diagnose Alzheimer’s disease at an early stage. Improved imaging techniques, biomarkers, and genetic testing have contributed to early detection and intervention, which, in turn, drives the demand for therapeutics.
Alzheimer’s therapeutics refers to the range of treatments and interventions designed to manage, treat, and potentially cure Alzheimer's disease, encompassing pharmacological treatments like cholinesterase inhibitors and NMDA receptor antagonists, emerging therapies such as immunotherapies and gene therapies, as well as non-pharmacological interventions like cognitive and behavioral therapies, lifestyle modifications, and supportive care.
Alzheimer’s Therapeutics Market Trends
The Alzheimer’s therapeutics industry is experiencing several notable trends that are shaping its growth and development. Factors such as continuous innovations in drug development, shift towards disease-modifying therapies, growing personalized medicine approaches, and surging need of integrated digital health technologies, among other factors are propelling the industry growth.
Alzheimer’s Therapeutics Market Analysis
Based on drug class, the market is classified into cholinesterase inhibitors, NMDA receptor antagonist, combination drugs, glutamate inhibitors, MAO inhibitors, and other drug classes. The cholinesterase inhibitors segment generated the highest revenue of USD 2.6 billion in 2023.
Based on route of administration, the Alzheimer’s therapeutics market is classified into oral, injectable, and transdermal patch. The oral segment dominated the market in 2023 with a market share of 58%.
Based on distribution channel, the Alzheimer’s therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2023 and is anticipated to reach USD 8.2 billion by the end of forecast period.
North America Alzheimer’s therapeutics market accounted for USD 2.2 billion market revenue in 2023 and is anticipated to grow during the forecast period.
Germany Alzheimer’s therapeutics market is projected to grow remarkably in the coming years.
Japan holds a dominant position in the Asia Pacific Alzheimer’s therapeutics market.
Alzheimer’s Therapeutics Market Share
The Alzheimer’s therapeutics industry is competitive in nature, with various large multinationals and small and mid-sized companies competing in the industry. The market is characterized by significant growth, driven by the increasing prevalence of Alzheimer’s disease, especially among the aging global population.
Market share is dominated by North America and Europe due to their advanced healthcare infrastructure, robust R&D capabilities, and strong regulatory frameworks. Major pharmaceutical companies such as Biogen, Eisai, and Eli Lilly lead in developing innovative treatments, including disease-modifying therapies and symptomatic treatments. Emerging markets in Asia-Pacific, particularly Japan and China, are also witnessing rapid growth due to rising awareness, improved healthcare facilities, and increased government support.
Alzheimer’s Therapeutics Market Companies
Prominent players operating in the Alzheimer’s therapeutics industry include:
Alzheimer’s Therapeutics Industry News:
The Alzheimer’s therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:
Click here to Buy Section of this Report
Market, By Drug Class
Market, By Route of Administration
Market, By Distribution Channel
The above information is provided for the following regions and countries: